SCHEMBL3604263

SCHEMBL3604263

NC(=O)c1ccc(OB(O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 18/20 0.61
PARP15 Q460N3 5/20 0.61
PARP4 Q9UKK3 2/20 0.61
PARP14 Q460N5 2/20 0.61
ALDH1A1 P00352 1/20 0.61
KMT2A Q03164 1/20 0.61
PARP16 Q8N5Y8 1/20 0.61
PARP11 Q9NR21 1/20 0.61
PARP2 Q9UGN5 4/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
PARP1 P09874 1/20 0.57
PARP3 Q9Y6F1 1/20 0.48
TNKS O95271 1/20 0.47
TNKS2 Q9H2K2 1/20 0.47
SENP8 Q96LD8 1/20 0.46
SENP6 Q9GZR1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL742375 0.80 CA1 (0.56) PARP10PARP15ALDH1A1KMT2ACA1
SCHEMBL28690614 0.78 CA1 (0.54) PARP10PARP15ALDH1A1KMT2ACA1
SCHEMBL28849890 0.78 ALDH1A1 (0.41) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL591298 0.78 MAPT (0.61) ALDH1A1KMT2A
Ammonia Solution, Strong SCHEMBL31590444 0.78 CA1 (0.54) PARP10PARP15ALDH1A1KMT2ACA1
SCHEMBL3800806 0.78 CA1 (0.38) KMT2ACA1CA2
SCHEMBL15259341 0.77 PARP10 (0.67) PARP10PARP15PARP4PARP14ALDH1A1
Ethylene SCHEMBL38650587 0.77 CA1 (0.52) PARP10PARP15ALDH1A1KMT2ACA1
SCHEMBL3137816 0.77 PARP10 (1.00) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL20293640 0.76 PARP1 (0.62) PARP10PARP15PARP14KMT2APARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144903-A1 RADIONUCLIDE-LABELED BORON-CONTAINING DRUG, AND PREPARATION AND USE THEREOF Chengdu New Radiomedicine Technology Co., Ltd. (CN) 2026-05-28 US claimed
EP-4667016-A1 BORON-CONTAINING DRUG AND PREPARATION METHOD THEREFOR Chengdu New Radiomedicine Technology Co., Ltd. (CN) 2025-12-24 EP claimed
EP-4667020-A1 RADIONUCLIDE-LABELED BORON-CONTAINING DRUG, AND PREPARATION AND USE THEREOF Chengdu New Radiomedicine Technology Co., Ltd. (CN) 2025-12-24 EP claimed
CN-116077685-B Radionuclide-labeled boron-containing medicament and preparation and application thereof 成都纽瑞特医疗科技股份有限公司 2024-11-26 CN claimed
CN-116077655-B Boron-containing medicine and its preparation method 成都纽瑞特医疗科技股份有限公司 2024-11-26 CN claimed
CN-111381458-B Photoresist cleaning solution 安集微电子科技(上海)股份有限公司 2024-04-30 CN claimed
CN-116574477-A High-temperature-resistant polyimide adhesive based on dynamic boron-oxygen bond and preparation method thereof 华南理工大学 2023-08-11 CN claimed
CN-113896188-B Preparation method of boron-doped graphene heat conducting film 中国科学院兰州化学物理研究所 2023-06-13 CN claimed
CN-116077685-A Radionuclide-labeled boron-containing medicament and preparation and application thereof 成都纽瑞特医疗科技股份有限公司 2023-05-09 CN claimed
CN-116077655-A Boron-containing medicine and its preparation method 成都纽瑞特医疗科技股份有限公司 2023-05-09 CN claimed
CN-113697808-B Transition metal oxide-loaded porous carbon material, and preparation method and application thereof 山东交通学院 2022-11-18 CN claimed
CN-105358611-B The method for manufacturing non-roasting type electrode E.I.内穆尔杜邦公司 2018-07-17 CN claimed
US-20260144903-A1 RADIONUCLIDE-LABELED BORON-CONTAINING DRUG, AND PREPARATION AND USE THEREOF Chengdu New Radiomedicine Technology Co., Ltd. (CN) 2026-05-28 US disclosed
EP-4667016-A1 BORON-CONTAINING DRUG AND PREPARATION METHOD THEREFOR Chengdu New Radiomedicine Technology Co., Ltd. (CN) 2025-12-24 EP disclosed
EP-4667020-A1 RADIONUCLIDE-LABELED BORON-CONTAINING DRUG, AND PREPARATION AND USE THEREOF Chengdu New Radiomedicine Technology Co., Ltd. (CN) 2025-12-24 EP disclosed
CN-116077685-B Radionuclide-labeled boron-containing medicament and preparation and application thereof 成都纽瑞特医疗科技股份有限公司 2024-11-26 CN disclosed
US-20090018056-A1 Heteroarylcarbamoylbenzene derivatives MSD K.K. (JP) 2009-01-15 US disclosed
US-7432287-B2 Heteroarylcarbamoylbenzene derivative BANYU PHARMECEUTICAL CO., LTD. (JP) 2008-10-07 US disclosed
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative MSD K.K. (JP) 2006-07-27 US disclosed
EP-1600442-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018056-A1 Heteroarylcarbamoylbenzene derivatives GCK, GCKR, KHK PARP10 2656/4885PARP15 3054/4885PARP4 2443/4885
US-20260144903-A1 RADIONUCLIDE-LABELED BORON-CONTAINING DRUG, AND PREPARATION AND USE THEREOF DBH, SLC39A11, GHRHR PARP10 3913/4885PARP15 1738/4885PARP4 2171/4885
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative GCK, GCKR, GALK1 PARP10 2883/4885PARP15 2663/4885PARP4 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.